To evaluate the efficacy and safety of Xuefuzhuyu decoction for hyperlipidemia.
INTRODUCTION
Hyperlipidemia, including elevated serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), is an independent risk factor for atherosclerosis. It can lead to coronary heart disease and ischemic stroke. 1, 2 The first phase of National Health and Nutrition Examination Survey (NHANES Ⅲ) (1988) (1989) (1990) (1991) indicated that 49% of adult Americans have a TC≥ 5.2 mmol/L (200 mg/dL). 3 An update of NHANES Ⅲ
from 1999-2000 reported that adult Americans age-standardized TC is 5.27 mmol/L (203 mg/dL). 4 Therefore, prevention and treatment of hyperlipidemia is very important. Common lipid-lowering drugs used in clinic at present include Hydroxy methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), phenoxy aromatic acids (fibrates), nicotinic acid and its derivatives, and other types of lipid-lowering drugs. All of the main lipid-lowering drugs, such as statins and fibrates, have certain side effects. Moreover, the combination of statins and fibrates has a high risk of side effects such as muscle damage and liver damage. More than 2000 plants are used in traditional herbal or alternative medical systems and some may provide relief to patients with cardiovascular diseases, especially those with hyperlipidemia and ischemic heart disease. In China, Japan, and other areas in Asia, the usage of herbs is based on Traditional Chinese Medicine (TCM) theory. Syndrome and disease differentiation are important to TCM. Therefore, hyperlipidemia in TCM is considered a blood stasis syndrome. Hyperlipidemia including hemodynamic changes and arterial plaque caused by hyperlipidemia, should be treated by activating blood and dissolving stasis. 5 Xuefuzhuyu decoction, which originated in the Qing Dynasty, is considered one of the most effective decoctions for activating blood and dissolving stasis related to the cardiovascular and cerebrovascular systems. The clinical use of Xuefuzhuyu decoction may improve blood circulation, and relieve the symptoms of angina or other cardiovascular diseases. 6 Some studies indicate that Xuefuzhuyu decoction is effective on hyperlipidemia. Therefore, a systematic review of clinical trials related to Xuefuzhuyu decoction and hyperlipidemia are reported in this study.
MATERIALS AND METHODS

Inclusion criteria for studies
Randomized controlled trials (RCTs) or quasi-RCTs, either in English or Chinese, regardless of journal, allocation concealment, or blinding method, were included in our analysis.
Inclusion and exclusion criteria for participants
Patients with hyperlipidemia were included regardless of their age, sex, or race if the diagnosis of hyperlipidemia was made by "Screening and management of lipids" 7 or any other reasonable criteria. Patients with diabetes, hypothyroidism, nephrotic syndrome, liver and gallbladder disease that could lead to secondary hyper-lipidemia were excluded. Those with severe heart, liver, or kidney disease, or severe infection were also excluded.
Primary and secondary outcomes
The primary outcome was lipid-lowering efficacy. Secondary outcomes were TC, LDL-C, triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) levels.
Outcome measurement
Efficacy evaluation criteria were determined according to "Chinese Adult dyslipidemia Prevention Guide" 8 and other guidelines. "Effective" was considered TC decreased >10% , TG decreased >20% , or one of the lipid indexes was restored to normal after intervention. "Invalid" was considered TC decreased <10%, TG decreased <20% , or none of the lipid indexes were restored to normal after intervention. "Worsened" was considered when TC or TG increased >10%, or other lipid indexes exceeded normal after intervention.
Literature search
The following electronic databases were searched since the beginning of the database to 2 May, 2013: Medical Literature Analysis and Retrieval System Online, Allied and Complementary Medicine Database, Excerpta Medica Database, The Cochrane Library 2013 (Issue 4), and three Chinese Databases: China National Knowledge Infrastructure Database, Chinese Biomedical Literature Database, and Wanfang Database. The search terms used were "Xuefuzhuyu", "lipid", "hyperlipidemia", "dyslipidemia", "hypercholesterolemia", and "hypertriglyceridemia". Various combinations of the search terms were used depending on the database. The type of publication was clinical study. Two reviewers (Weijiang Song and Weihan Zhao) worked independently for inclusion of studies. Any disagreements were resolved through discussion.
Data extraction and quality assessment
Articles were identified and selected independently by two reviewers (Jiaxing Tian, Beijing University of Chinese Medicine, and Tengfei Li, Beijing Hospital of Traditional Chinese Medicine, both of them had been trained in Beijing University of Chinese Medicine for identifying and selecting the articles) according to the established inclusion criteria. The methodological quality was assessed via the Cochrane Collaboration's risk of bias criteria: 9 (a) whether the random method is correct; (b) whether allocation concealment is used; (c) whether the blind method is used; and (d) whether lost cases are described and intent-to-treat analysis is used. If all the above quality standards were "adequate," it was unlikely that there would be any biases. However, if one criterion was "not clear," there was a moderate probability of corresponding bias. If one criterion was "inadequate" or "not used," there was a high probabili-ty of corresponding bias. Discrepancies were resolved by consensus through discussion between the two reviewers and, if needed, by asking for further evaluation from the other two reviewers (Jiangquan Liao, Beijing University of Chinese Medicine, and Jinhang Du, China-Japan Friendship Hospital). 10
Statistical analysis
The mean changes in TC, LDL-C, TG, and HDL-C compared with baseline were calculated in the Xuefuzhuyu decoction and control arms. These changes were used to assess the differences between the intervention and control groups. The odd risk (OR) of data was calculated if the variables were dichotomous data. The weighted mean difference (WMD) was calculated if the variables were continuous data. A 95% confidence interval (CI) was also calculated from the data using the Cochrane Collaboration's software. 11
RESULTS
Study description
A total of 105 articles were identified. After screening the titles and abstracts, 26 potentially relevant studies were found. After detailed evaluation of the full text, 20 some articles were excluded. Most articles were excluded because hyperlipidemia was only a complication, or lipids were not the main evaluating indexes. One article was excluded because it claimed that it was a RCT, but was actually a cohort study using healthy people without intervention as the control group. One article was excluded because it only reported differences between the treatment and control groups after treatment. Eventually, six articles met our inclusion criteria ( Figure 1 ). All studies were RCTs from China. Three 14, 16, 17 of the included trials used Xuefuzhuyu decoction plus simvastatin as the treatment group and simvastatin as the control group. Two studies 12, 13 used Xuefuzhuyu decoction alone as treatment and inositol nicotinate tablets as the control group. One trial 15 used Xuefuzhuyu decoction alone as the treatment group and Xuezhikang capsule (a Chinese patent medicine extracted from red yeast rice which can reduce lipids) as the control group. Detailed data of all the included research are summarized in Table 1 .
Quality assessment
All studies mentioned randomization but none described detailed randomization methods. Five showed no significant differences in baseline. None mentioned allocation concealment, blinding methods, or intention-to-treat. Therefore, all six studies had high probabilities of selection bias, performance bias, or measurement bias ( Table 2 ).
Efficacy evaluation
All six studies [12] [13] [14] [15] [16] [17] compared efficacy between the treatment group and the control group after intervention. The treatment group scored significantly higher than the control group [n=748, OR=5.07, 95% CI (3.40, 7.58), P<0.01]. Three 14, 16, 17 of the studies used Xuefuzhuyu decoction plus unspecified lipid-lowering drugs as the treatment group while three 12, 13, 15 used Xuefuzhuyu decoction alone as treatment. All of the subgroups showed that the treatment group was more effective than the control group [n=401, OR=5.49, 95% CI (3.02, 9.98), P<0.01 and n=347, OR=4.74, 95% CI (2.76, 8.14), P<0.01]. The efficacy evaluation in two studies 12, 13 is different from other studies. "Effective" should be classified until one or more lipid indexes reached normal. 12, 13 Compared with other included studies, this might lead to false "invalid" findings. The total outcome did not interfere with the results after excluding the two studes 12, 13 because the treatment group still scored higher than the control group [n=579, OR= 5.48, 95% CI (3.43, 8.75), P<0.01] (Figure 2 ). In the subgroup Xuefuzhuyu decoction plus lipid-lowering drugs, Xuefuzhuyu decoction was combined with conventional lipid-lowering drugs in the treatment group compared with only conventional lipid-lowering drugs in the control group. In the subgroup Xuefuzhuyu decoction alone, Xuefuzhuyu decoction was used alone in the treatment group compared with conventional lipid-lowering drugs in the control group.
Index evaluation
Four studies [14] [15] [16] [17] compared the effect of lowering TC between the treatment and control groups. The treatment group was significantly more effective than the control group [n=439, WMD=-0.79, 95% CI (-1.21, -0.36)]. Both of the subgroups, Xuefuzhuyu decoction plus lipid-lowering drugs and Xuefuzhuyu decoc- Excluded publications after reading the full text (n=20) ·Hyperlipidemia is only a complication or lipids is not the main evaluating index (n=15) ·Lack of detailed data (n=1) ·Case reports or cohort study (n=4)
Researches included in the systematic review (n=6) tion alone, showed effectiveness in lowering TC [n= 275, WMD=-0.85, 95% CI (-1.35, -0.34) and n= 164, WMD=-0.57, 95% CI (-0.98, -0.16)]. The differences exist in the test for subgroups differences (P<0.05 but P>0.01). In these four studies, only one 14 did not apply syndrome differentiation on the included patients to adjust the usage of herbal medicines. However, the patients were regarded as having blood stasis because the inclusion criteria included blood stasis. Additionally, the usage of Xuefuzhuyu decoction in one 14 study was based on syndrome differentiation. Both the Xuefuzhuyu decoction plus lipid-lowering drugs and the Xuefuzhuyu decoction alone were more effective than the control groups for lowering TC (Figure 3) . Only two studies 14, 16 recorded a comparison of LDL-C between the treatment group and the control group after intervention. The treatment group was significantly more effective than the control group in lowering LDL-C [n=158, WMD= -0.74, 95% CI ( -0.94, -0.55)]. Both of the studies used Xuefuzhuyu decoction plus simvastatin as treatment group and simvastatin alone as control group. One 16 study used syndrome differentiation and added certain herbal medicines based on the differentiation. One other study 14 also used differentiation. However, one 14 was not as effective as the other 16 (WMD=-0.57, 95% CI (-1.09, -0.05)] vs [WMD=-0.77, 95% CI (-0.98, -0.56)], and statistically the heterogeneity was low (P>0.05). This indicates that the confidence of the data integration was valid, and Xuefuzhuyu decoction plus simvastatin is more effective than simvastatin alone in lowering LDL-C (Figure 4) . Four studies [14] [15] [16] [17] compared the effect of lowering TG between the treatment group and the control group. The treatment group was significantly more effective than the control group in lowering TG [n=439, WMD=-0.40, 95% CI ( -0.59, -0.20)]. In the subgroup Xuefuzhuyu decoction plus lipid-lowering drugs as treatment, one 14 study did not show a significant difference in lowering TG between the treatment and control groups. However, meta-analysis showed that Xuefuzhuyu decoction plus lipid-lowering drugs was more effective than lipid-lowering drugs in lowering TG (heterogeneity: P>0.05). All three studies 14, 16, 17 in the subgroup Xuefuzhuyu decoction plus lipid-lowering drugs used simvastatin as the conventional lipid-lowering drug. Simvastatin usually lowers TC and LDL-C. Using TG-lowering drugs like fenofibrate could enhance the investigation of Xuefuzhuyu decoction for TG-lowering effectiveness. However, hyperlipidemia is always a combination of varying degrees of hypercholesterolemia and hypertriglyceridemia, and the combination of statins and fibrates could increase the chances side effects. Therefore, the lowering of TG after combination of Xuefuzhuyu decoction and simvastatin indicates that Xuefuzhuyu decoction could be an adjuvant or replacement therapy for hyperlipidemia. Efficacy, TC, TG,  LDL-C, HDL-C  Efficacy, TC, TG,  HDL-C   Efficacy, TC, TG,  LDL-C, HDL-C  Efficacy, TC, TG In this study, the author described only the basic information before grouping. Therefore, the comparisons between the treatment and control groups in gender, age, and course of hyperlipidemia are absent.
The subgroup that used Xuefuzhuyu decoction alone as treatment group, used Xuezhikang capsule as a control group. Xuezhikang capsule is a Chinese patent medicine mainly extracted from red yeast rice. Clinical trials and experimental research has shown that Xuezhikang capsule has certain lipid-lowering effects. 18, 19 One study 15 used syndrome differentiation, and showed that Xuefuzhuyu decoction alone was more effective than Xuezhikang capsule at lowering TG [n=164, WMD= -0.88, 95% CI (-1.51, -0.25)]. This indicates the importance of syndrome differentiation ( Figure 5 ). Four studies [14] [15] [16] [17] compared the effect on increasing HDL-C between the treatment group and the control group. The treatment group was more effective than the control group in significantly increasing HDL-C [n=439, WMD=0. 16 , 95% CI (0.04, 0.27)]. Three-studies 14, 16, 17 used Xuefuzhuyu decoction plus lipid-lowering drugs as a treatment group, while one 15 used Xuefuzhuyu decoction alone as a treatment group. The former subgroup showed that there was no statistical difference between the treatment group and the control group [n=275, WMD=0.15, 95% CI ( -0.04, 0.34)]. However, there was tendency for Xuefuzhuyu decoction plus lipid-lowering drugs to exceed lipid-lowering drugs in increasing HDL-C. After data integration of both subgroups, the difference is statistically significant (Figure 6 ).
Security
Two 14, 16 of all studies listed safety reports. Both studies used Xuefuzhuyu decoction plus lipid-lowering drugs in the treatment group. In the treatment group, four Study Hong B et al 2000 12 Tian YF 2001 13 Lei WN 2006 14 Wang XY 2009 15 Zeng XG 2011 16 Qiu 
Follow-up
None of these RCTs included follow-up.
DISCUSSION
Based on the results, Xuefuzhuyu decoction may be able to treat hyperlipidemia with no significant side effects. However, all of the studies in this review had low methodology quality and the sample sizes were small. These studies lacked the details of randomization, allocation concealment, and blinding methods, which lead to inability to judge whether the study was conducted properly. There were no multi-center or large-scale ran- domized clinical trials about Xuefuzhuyu decoction in treating hyperlipidemia. Therefore, the use of Xuefuzhuyu decoction for hyperlipidemia is not adequate. According to this systematic review, Xuefuzhuyu decoction could enhance the effectiveness of lipid-lowering drugs. Moreover, Xuefuzhuyu decoction showed effectiveness in lowering TG, which provides more flexible choices in treatment protocols for hyperlipidemia. The application of syndrome differentiation based on TCM theory is very important in the usage of Chinese herbal medicines. According to this systematic review, Xuefuzhuyu decoction could be used in hyperlipidemia patients with different syndromes based on the guidance of accurate differentiation. The methodological quality of these clinical trials for Xuefuzhuyu decoction should be improved. Evaluating the efficacy of Xuefuzhuyu decoction on hyperlipidemia requires more strictly designed large-scale randomized clinical trials. Figure 6 Meta-analysis of HDL-C HDL-C: high-density lipoprotein cholesterol. Xuefuzhuyu decoction group vs control group. After data integration of both subgroups, the difference is statistically significant.
